Nasdaq:WVE
Wave Life Sciences Ltd.
A pre-commercial biotech firm generating revenue from strategic collaborations while aggressively funding its pipeline with substantial cash reserves exceeding $600M.
Key Metrics
Investment Thesis
Bull Case
With a net change in cash of $300M and over $600M in liquid assets, the company is well-capitalized to survive long development cycles, making it an attractive speculative play for investors betting on the eventual success of its oncology pipeline.
Bear Case
The widening deficit from -$97.0M to -$204.4M over two years suggests a deteriorating financial trajectory where revenue growth has stalled and operating expenses are outpacing income, posing a severe threat to solvency if financing dries up.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics primarily for oncology and rare diseases, with significant R&D investments in 2025 totaling $182.8M.
Analysis
Management Discussion
Despite a massive influx of $488.2M from financing activities that increased cash by $300M year-over-year, operating losses have deepened significantly, with R&D spending alone consuming the majority of the $42.7M revenue generated in 2025.
Industry Overview
Wave Life Sciences operates in the highly competitive clinical-stage biotechnology sector where companies often operate at losses while awaiting FDA approval for novel therapeutics targeting oncology and rare diseases.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $3.6M | $113.3M | $108.3M | $42.7M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $3.6M | $113.3M | $108.3M | $42.7M |
| Operating Expenses | $166.4M | $181.3M | $218.7M | $258.1M |
| Operating Income | $-162.7M | $-68.0M | $-110.4M | $-215.4M |
| R&D | $115.9M | $130.0M | $159.7M | $182.8M |
| G&A | $50.5M | $51.3M | $59.0M | $75.3M |
| Stock-Based Comp | $17.2M | $9.8M | $13.1M | $25.0M |
| Depreciation | $6.6M | $5.0M | $3.9M | $3.4M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $1.6M | $9.8M | $13.4M | $11.0M |
| Pre-Tax Income | $-161.1M | $-58.2M | $-97.0M | $-204.4M |
| Income Tax | $681.0K | $-677.0K | $0 | $0 |
| Continuing Ops | $-161.8M | $-57.5M | $-97.0M | $-204.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-161.8M | $-57.5M | $-97.0M | $-204.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-161.8M | $-57.5M | $-97.0M | $-204.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $98.5M | $235.4M | $320.4M | $614.8M |
| Cash & Equivalents | $88.5M | $200.4M | $302.1M | $602.1M |
| Accounts Receivable | — | $21.1M | $1.4M | $1.3M |
| Other Current Assets | $10.0M | $13.9M | $16.9M | $11.5M |
| Long-Term Assets | $47.8M | $39.6M | $31.8M | $23.7M |
| PP&E (Net) | $17.3M | $13.1M | $10.1M | $7.4M |
| Operating Leases | $26.8M | $22.6M | $17.9M | $12.5M |
| Other LT Assets | $3.7M | $3.9M | $3.8M | $3.8M |
| Total Assets | $146.4M | $274.9M | $352.2M | $638.5M |
| Current Liabilities | $71.5M | $186.4M | $111.0M | $95.1M |
| Accounts Payable | $16.9M | $12.8M | $16.3M | $15.7M |
| Current Leases | $5.5M | $6.7M | $7.6M | $8.4M |
| Deferred Revenue | $31.6M | $150.1M | $66.0M | $44.4M |
| Other Current Liab | $14.0M | $15.1M | $16.5M | $19.2M |
| Long-Term Liabilities | $112.1M | $41.0M | $23.9M | $17.2M |
| LT Operating Leases | $32.1M | $25.4M | $17.8M | $9.4M |
| Other LT Liab | $190.0K | $0 | $0 | $0 |
| Total Liabilities | $183.6M | $227.4M | $134.8M | $112.3M |
| Shareholders' Equity | $-37.2M | $47.5M | $217.4M | $526.2M |
| Paid-In Capital | $119.4M | $129.2M | $156.5M | $228.4M |
| Retained Earnings | $-967.3M | $-1.02B | $-1.12B | $-1.33B |
| AOCI | $-29.0K | $-124.0K | $-262.0K | $-250.0K |
| Total L&E | $146.4M | $274.9M | $352.2M | $638.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-161.8M | $-57.5M | $-97.0M | $-204.4M |
| Non-Cash Adjustments | $27.1M | $-36.6M | $48.7M | $37.4M |
| Working Capital Changes | $6.9M | $74.7M | $-102.7M | $-20.5M |
| Cash from Operations | $-127.8M | $-19.4M | $-151.0M | $-187.5M |
| Capital Expenditures | $1.4M | $1.1M | $938.0K | $718.0K |
| Cash from Investing | $-1.3M | $-1.1M | $-938.0K | $-718.0K |
| Cash from Financing | $67.2M | $132.5M | $253.9M | $488.2M |
| FX Effect | $-210.0K | $-95.0K | $-138.0K | $12.0K |
| Net Change in Cash | $-62.1M | $111.9M | $101.8M | $300.0M |
| Beginning Cash | $154.2M | $92.2M | $204.1M | $305.8M |
| Ending Cash | $92.2M | $204.1M | $305.8M | $605.9M |
Frequently Asked Questions
How does Wave Life Sciences Ltd. make money?
The company's financial profile indicates revenue derived largely from licensing agreements and commercialization partnerships, supported by massive operating expenses driven by research and development ($182.8M) and general administrative costs ($75.3M), with no cost of revenue suggesting a service or intellectual property licensing model.
What are the main risks for WVE?
Significant losses have widened from -$57.5M in 2023 to -$204.4M in 2025, indicating unsustainable burn rates without new major partnerships; the company faces high regulatory hurdles typical of clinical-stage biotechs and potential dilution if cash reserves deplete before product approval.
What is WVE's competitive advantage?
The firm leverages a robust balance sheet with $602.1M in cash and equivalents to fund high-risk pipeline development without immediate dilution, alongside specialized expertise in oncology and rare disease therapeutics that differentiates its R&D efforts.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.